Year: 2021

NeuroMetrix Announces That Top-Line Results from a Randomized Controlled Trial of Quell® for Treatment of Fibromyalgia to be Presented at Two Upcoming Pain Medicine Conferences

WOBURN, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported that top-line results from a randomized...

Kymera Therapeutics to Present New Data Demonstrating both Single-agent and Combination Regressions in MYD88-mutant Lymphoma Preclinical Models with IRAKIMiD Degrader KT-413 at 16th ICML Meeting

Data demonstrate KT-413’s potential as a monotherapy and in combination with rituximab or BTK inhibitors, with potent antitumor activity in...

New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern

Adaptive’s immunoSEQ T-MAP COVID provides potential explanation for preservation of Johnson & Johnson vaccine (Ad26.COV2.S) response to variants even when...

error: Content is protected !!